Insomnia News and Research

Latest Insomnia News and Research

Sleep deprivation may increase heart attack risk

On average, people go to work or school on the first Monday of Daylight Savings after sleeping 40 fewer minutes than normal. And recent studies have found there's a higher risk of heart attacks, traffic accidents and workplace injuries on the first Monday of Daylight Savings.

11 Mar 2010

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Many Americans will lose an hour of sleep on March 14, the first day of daylight-saving time, when clocks are set ahead one hour at 2 a.m. local standard time—making it harder to wake up, causing difficulty in staying alert and increasing the chance of sleepy-driving car crashes.

11 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

NSF's Sleep in America poll finds differences in sleep habits and attitudes among ethnic groups

The 2010 Sleep in America poll released today by the National Sleep Foundation reveals significant differences in the sleep habits and attitudes of Asians, Blacks/African-Americans, Hispanics and Whites. It is the first poll to examine sleep among these four ethnic groups.

8 Mar 2010

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Promises Treatment Center CEO's insights on Redmond O'Neal's addiction and rehabilitation problems

The unfortunate story of Redmond O'Neal continues to make headlines. He has been an admitted addict since he was a teen and has had multiple drug arrests. He recently appeared in court for a status hearing on his latest stint in rehab.

5 Mar 2010

Neurocrine Biosciences to sell common stock shares

Neurocrine Biosciences, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is the sole book-running manager for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

5 Mar 2010

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

5 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck & Co., Inc. today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.

3 Mar 2010

Stanford University Medical Center buys ASTI's Ecotones Duet Adaptive Sleep Sound Machines

Adaptive Sound Technologies, Inc. (ASTI) announced today that the Stanford University Medical Center has purchased Ecotones Duet Adaptive Sleep Sound Machines. "It is well known that noise in hospitals affects patient comfort and recovery, as well as staff performance. ASTI's adaptive technology can help with these problems," stated Sam Nicolino, President and CEO of ASTI.

3 Mar 2010

PTSD drug: Cannabis Science to file first application for FDA clinical trials

Cannabis Science Inc., a pharmaceutical cannabis company in the US, is pleased to announce that it now has the results of its survey of more than 1,300 individuals with PTSD, including a large cohort of veterans. The survey was conducted by Cannabis Science Advisory Board member Dr. Mitch Earleywine PhD. of the State University of New York (Albany).

2 Mar 2010

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Acorda Therapeutics, Inc. today announced that AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg is now available by prescription in the United States and Puerto Rico. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is indicated for use in all types of MS, and can be used either alone or with existing therapies, including disease-modifying agents.

1 Mar 2010

Study challenges psychiatrists' official diagnostic manual in preventing mistaken diagnoses of depression

A study in the March edition of the American Journal of Psychiatry senior-authored by Jerome C. Wakefield, a professor at the Silver School of Social Work at New York University with Mark Schmitz of Temple University and Judith Baer of Rutgers University, empirically challenges the effectiveness of psychiatrists' official diagnostic manual in preventing mistaken, false-positive diagnoses of depression.

25 Feb 2010

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Fisher Wallace Laboratories today announced that two psychiatry professors at Columbia University, Dr. Richard Brown and Dr. Andres San Martin, have prescribed the Fisher Wallace Cranial Stimulator to more than 250 patients suffering from depression, anxiety and insomnia.

25 Feb 2010

Combination therapies effective for treating depression

Even after she left her alcoholic, abusive husband behind, Patrice, a nurse in Florida, couldn't summon the energy to keep her house straight, couldn't sleep.

24 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

Study shows prevalence of depression among low-income urban mothers

More than half of low-income urban mothers met the criteria for a diagnosis of depression at some point between two weeks and 14 months after giving birth, according to a study led by University of Rochester Medical Center researchers and published online by the journal Pediatrics.

19 Feb 2010

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

19 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Insomnia News and Research

Latest Insomnia News and Research

Sleep deprivation may increase heart attack risk

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

NSF's Sleep in America poll finds differences in sleep habits and attitudes among ethnic groups

Presentation of results from open-label extension study of Xenazine

Promises Treatment Center CEO's insights on Redmond O'Neal's addiction and rehabilitation problems

Neurocrine Biosciences to sell common stock shares

KAPIDEX to be marketed as DEXILANT in the U.S.

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Stanford University Medical Center buys ASTI's Ecotones Duet Adaptive Sleep Sound Machines

PTSD drug: Cannabis Science to file first application for FDA clinical trials

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Study challenges psychiatrists' official diagnostic manual in preventing mistaken diagnoses of depression

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Combination therapies effective for treating depression

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Study shows prevalence of depression among low-income urban mothers

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Insomnia News and Research

Latest Insomnia News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in